Xtant Medical Holdings Inc (XTNT)
Official siteHEALTHCARE • MEDICAL DEVICES • AMEX
Market Cap: $38.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Xtant Medical Holdings Inc (XTNT) Financials: Revenue, Profit and Cash Flow
Xtant Medical Holdings reported revenue of $133.93M for the fiscal year ended Dec 31, 2025, up 14.2% from the year before. That year, net income was $4.97M with a net margin of 3.7%, operating cash flow was $12.55M and free cash flow was $10.16M. The quarter ended Sep 30, 2026 had revenue of $24.29M and net income of -$3.56M.
Revenue and Margins
The operating margin was 5.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $90.00M, a compound annual rate of 4.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $133.93M | +14.2% | 62.9% | 5.4% | 3.7% |
| Dec 2024 | $117.27M | +28.4% | 58.2% | -10.3% | -14.0% |
| Dec 2023 | $91.30M | +57.5% | 60.8% | -11.1% | 0.7% |
| Dec 2022 | $57.97M | +4.9% | 55.4% | -11.7% | -14.6% |
| Dec 2021 | $55.26M | +3.6% | 58.8% | -7.0% | -8.8% |
| Dec 2020 | $53.34M | -17.5% | 64.5% | -1.4% | -13.2% |
| Dec 2019 | $64.68M | -10.4% | 65.7% | -3.5% | -12.7% |
| Dec 2018 | $72.20M | -12.6% | 60.2% | -83.2% | -97.1% |
| Dec 2017 | $82.61M | -8.2% | 60.6% | -45.8% | -63.4% |
| Dec 2016 | $90.00M | N/A | 69.2% | -8.4% | -21.7% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.93M | $117.27M | $91.30M | $57.97M | $55.26M | $53.34M | $64.68M | $72.20M | $82.61M | $90.00M |
| Cost of revenue | $49.65M | $49.05M | $35.84M | $25.83M | $22.77M | $18.95M | $22.17M | $28.72M | $32.51M | $27.71M |
| Gross profit | $84.27M | $68.22M | $55.47M | $32.14M | $32.49M | $34.39M | $42.52M | $43.49M | $50.10M | $62.29M |
| Research and development | $2.10M | $2.38M | $1.34M | $915.00K | $870.00K | $657.00K | $932.00K | $1.70M | $2.44M | $3.41M |
| Operating income | $7.28M | -$12.07M | -$10.16M | -$6.75M | -$3.85M | -$751.00K | -$2.25M | -$60.08M | -$37.83M | -$7.55M |
| Net income | $4.97M | -$16.45M | $660.00K | -$8.48M | -$4.85M | -$7.02M | -$8.22M | -$70.10M | -$52.41M | -$19.49M |
| EBITDA | $15.80M | -$7.88M | $4.93M | -$5.46M | -$2.52M | $1.33M | $792.00K | -$53.36M | -$29.30M | $61.43K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.29M | $23.03M | $20.88M | $32.36M | $33.26M | $35.41M | $32.90M | $31.51M | $27.94M | $29.94M | $27.87M | $28.11M |
| Gross profit | $13.66M | $13.33M | $11.97M | $17.75M | $21.99M | $24.28M | $20.24M | $16.02M | $16.31M | $18.58M | $17.30M | $17.14M |
| Operating income | -$3.03M | -$9.17M | -$2.92M | -$944.00K | $2.54M | $4.62M | $1.06M | -$1.88M | -$3.78M | -$2.95M | -$3.47M | -$3.81M |
| Net income | -$3.56M | -$9.41M | -$3.09M | $57.00K | $1.31M | $3.55M | $58.00K | -$3.16M | -$5.02M | -$3.86M | -$4.40M | -$4.30M |
Balance Sheet
As of Dec 2025, total debt of $25.38M exceeded cash and equivalents by $8.33M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $94.14M | $93.84M | $92.61M | $60.23M | $54.69M | $41.47M | $43.16M | $46.42M | $105.70M | $144.10M |
| Current assets | $78.25M | $67.12M | $64.87M | $49.32M | $44.33M | $31.36M | $32.25M | $34.68M | $39.70M | $48.99M |
| Cash and equivalents | $17.05M | $6.20M | $5.71M | $20.30M | $18.24M | $2.34M | $5.24M | $6.80M | $2.86M | $2.58M |
| Total liabilities | $43.19M | $50.87M | $41.26M | $26.06M | $23.81M | $26.95M | $87.36M | $90.19M | $164.40M | $151.17M |
| Short-term debt | $14.36M | $12.12M | $4.62M | $5.71M | $3.62M | $16.80M | $0 | $852.00K | $366.00K | $10.69M |
| Long-term debt | $11.03M | $22.04M | $17.17M | $9.69M | $11.79M | $0 | $76.24M | $77.94M | $137.96M | $50.28M |
| Shareholder equity | $50.95M | $42.96M | $51.35M | $34.17M | $30.88M | $14.51M | -$44.20M | -$43.77M | -$58.70M | -$7.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $75.22M | $79.67M | $78.00M | $94.14M | $106.32M | $103.48M | $95.83M | $93.84M | $98.88M | $95.58M | $93.93M | $92.61M |
| Total liabilities | $37.96M | $39.65M | $29.40M | $43.19M | $55.94M | $54.98M | $51.96M | $50.87M | $53.16M | $50.57M | $46.25M | $41.26M |
| Cash and equivalents | $7.79M | $9.87M | $12.14M | $17.05M | $10.40M | $6.92M | $5.03M | $6.20M | $6.60M | $5.38M | $4.55M | $5.71M |
| Shareholder equity | $37.26M | $40.02M | $48.60M | $50.95M | $50.38M | $48.50M | $43.88M | $42.96M | $45.73M | $45.01M | $47.68M | $51.35M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 81.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $12.55M | -$11.90M | -$9.52M | -$5.34M | $439.00K | -$731.00K | -$413.00K | $1.21M | -$543.00K | -$14.41M |
| Capital expenditures | $2.38M | $4.11M | $1.46M | $1.76M | $2.12M | $1.54M | $879.00K | $624.00K | $1.64M | $5.83M |
| Free cash flow | $10.16M | -$16.01M | -$10.97M | -$7.11M | -$1.68M | -$2.28M | -$1.29M | $588.00K | -$2.18M | -$20.24M |
| Dividends paid | N/A | N/A | N/A | N/A | $201.00K | N/A | N/A | N/A | N/A | $0 |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $3.36M | $0 | N/A |
| Investing cash flow | $7.90M | -$3.73M | -$24.78M | -$1.56M | -$1.89M | -$1.30M | -$544.00K | -$367.00K | -$1.61M | -$5.82M |
| Financing cash flow | -$9.57M | $16.07M | $19.69M | $9.02M | $17.50M | -$861.00K | -$603.00K | $3.10M | $2.43M | $16.43M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$855.00K | -$7.31M | -$2.11M | $5.38M | $4.61M | $1.28M | $1.28M | $665.00K | -$1.72M | -$5.09M | -$5.75M | -$915.00K |
| Capital expenditures | $389.00K | $247.00K | $194.00K | $395.00K | $430.00K | $366.00K | $1.19M | $672.00K | $2.10M | $564.00K | $773.00K | $363.00K |
| Free cash flow | -$1.24M | -$7.55M | -$2.31M | $4.99M | $4.18M | $910.00K | $87.00K | -$7.00K | -$3.82M | -$5.65M | -$6.53M | -$1.28M |
Frequently Asked Questions About XTNT
What is Xtant Medical Holdings' annual revenue?
Xtant Medical Holdings reported revenue of $133.93M for the fiscal year ended Dec 31, 2025.
How fast is Xtant Medical Holdings' revenue growing?
Revenue was up 14.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 32.2%.
Is Xtant Medical Holdings profitable?
Yes. Xtant Medical Holdings reported net income of $4.97M for the fiscal year ended Dec 31, 2025, with a net margin of 3.7%.
How much free cash flow does XTNT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $12.55M minus capital expenditures of $2.38M produced free cash flow of $10.16M.
How much debt does Xtant Medical Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $11.03M, short-term debt of $14.36M and cash and equivalents of $17.05M.
XTNT pages: Overview, Earnings, Forecast, Financials, Competitors